...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>OncoTargets and therapy >Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma
【24h】

Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma

机译：监测高密度脂蛋白胆固醇水平可预测晚期肺腺癌患者的EGFR突变和EGFR-TKI的疗效

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

High-density lipoprotein cholesterol (HDL-C) has an inverse association with the incidence of lung cancer. However, whether it can be used as a predictive factor in advanced lung adenocarcinoma patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) still remains undefined. This research aimed at studying the relationship of serum HDL-C baseline level and HDL-C kinetics to EGFR mutation, the efficacy of EGFR-TKI, and the predictive value of PFS. The presence of mutation rate in the 192 patients with lung adenocarcinoma was compared within stratified groups. Levels of baseline HDL-C and kinetics of HDL-C were analyzed retrospectively in patients treated with EGFR-TKI harboring EGFR mutation. Univariate and multivariate analyses were performed to investigate the prognostic value of HDL-C. EGFR mutation rate of HDL-C high-level group was significantly higher than that of low-level group (59.0% vs 35.6%, P =0.001). Multivariate logistic analysis showed that high-level HDL-C was an independent predictive factor for EGFR gene mutation ( P =0.005; odds ratio =0.417; 95% confidence interval [CI], 0.227–0.768). Patients with a low level of HDL-C before therapy showed a progression of disease in most cases ( P <0.001). According to HDL-C kinetics, patients who received EGFR-TKI treatment harboring EGFR mutation were divided into four groups. Univariate analysis showed that patients in nondecreased group had longer progression-free survival ( P <0.001; hazard ratio =0.003; 95% CI, 0.001–0.018). Multivariate Cox proportional hazards model analyses showed the same result ( P <0.001; hazard ratio =0.003; 95% CI, 0.001–0.018). Current results suggest that HDL-C seems to be a good independent predictive biomarker for advanced lung adenocarcinoma patients treated with the first-line EGFR-TKI. Roles of this biomarker include indicating EGFR mutation, assessing the efficacy of EGFR-TKI, and predicting the progression-free survival.
机译：高密度脂蛋白胆固醇（HDL-C）与肺癌的发生率呈负相关。但是，是否可以将其用作经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗的晚期肺腺癌患者的预测因子仍然不确定。这项研究旨在研究血清HDL-C基线水平和HDL-C动力学与EGFR突变的关系，EGFR-TKI的疗效以及PFS的预测价值。在分层组中比较了192例肺腺癌患者中突变率的存在。回顾性分析了具有EGFR突变的EGFR-TKI患者的基线HDL-C水平和HDL-C动力学。进行单因素和多因素分析以研究HDL-C的预后价值。 HDL-C高水平组的EGFR突变率显着高于低水平组（59.0％比35.6％，P = 0.001）。多元逻辑分析表明，高水平的HDL-C是EGFR基因突变的独立预测因素（P = 0.005;比值比= 0.417; 95％置信区间[CI]，0.227-0.768）。治疗前HDL-C水平低的患者在大多数情况下显示疾病进展（P <0.001）。根据HDL-C动力学，将接受EGFR-TKI治疗且携带EGFR突变的患者分为四组。单因素分析显示，非降低组患者的无进展生存期更长（P <0.001;危险比= 0.003; 95％CI，0.001-0.018）。多元Cox比例风险模型分析显示了相同的结果（P <0.001;风险比= 0.003; 95％CI，0.001-0.018）。目前的结果表明，HDL-C似乎是用一线EGFR-TKI治疗的晚期肺腺癌患者的良好独立预测生物标志物。该生物标志物的作用包括指示EGFR突变，评估EGFR-TKI的功效以及预测无进展生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号